Partnering

Micropoint is committed to finding and developing the world’s best biomarkers, antibodies, technologies, and developing them into a rapid diagnostic system. Accessing external innovation and expertise is a crucial part of our R&D strategy. Each scientist at Micropoint has a successful track-record of working closely with external partner companies, and leading academic researchers around the world in the clinical diagnostic areas. Including:

• Novel tumor biomarker clinical study with fluorescence based RIDA technology
• Compact, handheld MEMS based optical reader
• Novel biomarkers study on mLabs® platform
• Transfer central Lab ELISA test kits to mLabs® platform
• Transfer qualitative lateral flow tests into quantitative ezLabs® platform
• Customerizing antibodies to mLabs®
• Advanced bio-signal amplification technologies

At Micropoint, we will continue to maintain our network of collaborative and consultative relationships. Micropoint always looks forward to working with partners to provide novel diagnostics on demand. Micropoint also looks forward to the challenge of transforming key partnerships into strategic alliances. And last, but not least, Micropoint always looks forward to the real rewards coming through partnerships that work in the long run.

Let’s talk and explore what we can do together to make a better world!